- Home
- DXLG vs CVM Comparison
DXLG vs CVM Comparison
Compare DXLG & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | CVM |
|---|---|---|
| Founded | 1976 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 24.1M |
| IPO Year | 1994 | 1996 |
Fundamental Metrics
Financial Performance| Metric | DXLG | CVM |
|---|---|---|
| Price | $0.41 | $1.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.13 | ★ $12.50 |
| AVG Volume (30 Days) | 66.4K | ★ 104.2K |
| Earning Date | 12-03-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $435,017,000.00 | $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.36 | $0.89 |
| 52 Week High | $1.58 | $7.80 |
Technical Indicators
Market Signals| Indicator | DXLG | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 36.99 |
| Support Level | $0.40 | $1.19 |
| Resistance Level | $0.55 | $1.52 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 8.08 | 11.86 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store and Direct business. The company have two principal operating segments: company's stores and direct business.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.